APDS clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for

  • Pediatric Patients Aged 1 to 6 Years With APDS

    open to eligible people ages 1-6

    This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 1 to 6 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)

    Los Angeles, California and other locations

  • Pediatric Patients Aged 4 to 11 Years With APDS

    Sorry, in progress, not accepting new patients

    This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

    Los Angeles, California and other locations

Last updated: